Interaction between the renin-angiotensin system and insulin-like growth factor I in aorto-caval fistula-induced cardiac hypertrophy in rats.
The effects of angiotensin converting enzyme inhibition and angiotensin II receptor blockade on the development of cardiac hypertrophy and myocardial insulin-like growth factor I (IGF-I) in volume overload were studied in male Wistar rats with aorto-caval fistulas (ACF). Rats were treated with ramipril (RAM, 3 mg kg(-1) day(-1)) for 4-20 days or losartan (LOS, 10 mg kg(-1) day(-1)) for 2-7 days. Myocardial IGF-I and IGF-I receptor (IGF-I-R) mRNA were determined by solution hybridization. ACF caused hypertrophy of left (LV) and right ventricles (RV). Hypertrophy appeared on day 2 and reached maximal values of +60% in LV and +75% in RV at day 12. Systolic blood pressure was initially reduced 15% but recovered by day 12. RAM abolished the recovery of blood pressure. Furthermore, RAM attenuated RV hypertrophy by 17% on day 7 and on day 20, RV weights were close to values found in controls. Beginning on day 9, RAM reduced LV weight back to control levels in parallel to blood pressure. In contrast, LOS affected neither RV nor LV hypertrophy. RV IGF-I mRNA increased 60-100% on day 7 alone in RV in ACF. RAM potentiated the increase in RV IGF-I to +400% and induced an increase in RV IGF-I-R mRNA on day 7 (+90%) in ACF. LOS did not affect RV IGF-I. Development of cardiac hypertrophy in ACF seemed independent of angiotensin II. RV hypertrophy was associated with activation of IGF-I independent of the renin-angiotensin system. IGF-I was further potentiated when development of hypertrophy was attenuated, possibly indicative of a greater urge for compensational growth in a relatively thinner and more volume-distended chamber.
Wåhlander
H
H
Department of Physiology, Institute of Physiology and Pharmacology and Research Center for Endocrinology and Metabolism, Göteborg University, Sweden.
Wickman
A
A
Isgaard
J
J
Friberg
P
P
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000818:Animals; D000959:Antihypertensive Agents / Q000627:therapeutic use; D001012:Aorta, Abdominal; D001018:Aortic Diseases / Q000150:complications / Q000188:drug therapy / Q000378:metabolism*; D001164:Arteriovenous Fistula / Q000150:complications / Q000188:drug therapy / Q000378:metabolism*; D006332:Cardiomegaly / Q000188:drug therapy / Q000209:etiology* / Q000378:metabolism; D004195:Disease Models, Animal; D005500:Follow-Up Studies; D006439:Hemodynamics; D007334:Insulin-Like Growth Factor I / Q000187:drug effects / Q000235:genetics / Q000378:metabolism*; D019808:Losartan / Q000627:therapeutic use; D008297:Male; D009206:Myocardium / Q000378:metabolism; D010865:Pilot Projects; D012333:RNA, Messenger / Q000096:biosynthesis; D017257:Ramipril / Q000627:therapeutic use; D051381:Rats; D017208:Rats, Wistar; D017526:Receptor, IGF Type 1 / Q000187:drug effects / Q000235:genetics / Q000378:metabolism; D012084:Renin-Angiotensin System / Q000187:drug effects / Q000502:physiology*; D014682:Vena Cava, Inferior
D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D012333:RNA, Messenger; D007334:Insulin-Like Growth Factor I; D017526:Receptor, IGF Type 1; D019808:Losartan; D017257:Ramipril